Abstract
Hepatitis B can develop in less than 5% of neonates of infected mothers, despite neonatal serovaccination. Most children will develop a chronic hepatitis. Most children are in an immune-tolerant or in an inactive phase. Interferon is the treatment of choice, in the rare cases where it is necessary.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Antiviral Agents / therapeutic use
-
Carrier State
-
Child
-
DNA, Viral / blood
-
Female
-
Hepatitis B / immunology
-
Hepatitis B / transmission
-
Hepatitis B Surface Antigens / blood
-
Hepatitis B e Antigens / blood
-
Hepatitis B, Chronic / epidemiology
-
Hepatitis B, Chronic / therapy*
-
Humans
-
Immune Tolerance
-
Infectious Disease Transmission, Vertical
-
Interferons / therapeutic use
-
Pregnancy
-
Watchful Waiting
Substances
-
Antiviral Agents
-
DNA, Viral
-
Hepatitis B Surface Antigens
-
Hepatitis B e Antigens
-
Interferons